Current and Future Treatments in Primary Ciliary Dyskinesia

Area of Science:

• Genetics
• Pulmonology
• Rare Diseases

Background:

• Primary ciliary dyskinesia (PCD) is a rare genetic ciliopathy characterized by impaired mucociliary clearance due to ciliary dysfunction.
• This leads to recurrent airway infections, progressive lung damage, and potential respiratory failure.
• Current treatment guidelines for PCD are often adapted from cystic fibrosis (CF) due to limited PCD-specific research.

Purpose of the Study:

• To provide a comprehensive review of clinical studies investigating Primary ciliary dyskinesia (PCD) to date.
• To explore emerging precision medicine strategies for treating PCD.
• To highlight the current gaps in PCD research and treatment.

Main Methods:

• Systematic review of published clinical trials and case reports on PCD.
• Analysis of existing treatment strategies and their efficacy.
• Exploration of novel therapeutic avenues, including gene therapy, mRNA transcript, and read-through therapy.

Main Results:

• The review encompasses three clinical trials and several case reports on PCD.
• Current management focuses on improving mucociliary clearance and treating infections, with no definitive causative treatments available.
• Precision medicine approaches show promise for future PCD therapies.

Conclusions:

• There is a critical need for more PCD-specific clinical research and evidence-based treatment guidelines.
• Precision medicine, including gene and mRNA therapies, represents a promising frontier for addressing the underlying causes of PCD.
• Further investigation into these novel therapies is essential for developing effective treatments for patients with Primary ciliary dyskinesia.